3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
32
Neoplasm Metastasis
4
Metastatic Castration-Resistant Prostate Cancer
2
Newly Diagnosed Oligometastatic Prostate Cancer
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration Resistant Prostate Cancer
1
Castration-resistant Prostate Cancer
1
Castrate Sensitive Prostate Cancer
1
Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy
1
Advanced Prostate Carcinoma
1
Interventions
enzalutamide
9
Abiraterone Acetate
5
rucaparib
2
Prednisone
2
Docetaxel
2
pembrolizumab
1
fluzoparib
1
apatinib
1
abiraterone
1
Blood Specimen Collection
1
Biopsy
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Metastatic Castration Resistant Prostate Cancer
×
abiraterone
×
Clear all
NCT04179396
2023-06-29
RAMP
pharmaand GmbH
Phase 1
Completed
8 enrolled
8 charts